Cargando…
Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia
Management of patients with metastatic squamous cell skin cancer, refractory to initial therapy with standard chemotherapy and radiation protocols, remains difficult with poor overall prognosis and limited therapeutic options. Recently, promising response rates with nivolumab, a programmed death rec...
Autores principales: | Schwab, K.S., Heine, A., Weimann, T., Kristiansen, G., Brossart, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939691/ https://www.ncbi.nlm.nih.gov/pubmed/27462240 http://dx.doi.org/10.1159/000447508 |
Ejemplares similares
-
Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018) -
Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
por: Schwab, Katjana S., et al.
Publicado: (2019) -
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy
por: Palla, Amruth R., et al.
Publicado: (2016) -
Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain
por: Galindo-Navarro, Pablo, et al.
Publicado: (2023) -
Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia
por: Hamamyh, Tahseen, et al.
Publicado: (2020)